Trypanosomatid and fungal glycolipids and sphingolipids as infectivity factors and potential targets for development of new therapeutic strategies.
Several (glyco)(sphingo)lipids from different human pathogens have been characterized, and frequently many of these molecules are participating in host-pathogen interaction. In Leishmania (Leishmania) amazonensis, for example, amastigotes present on their surface glycosphingolipids (GSLs) with the structure Galbeta1-3Galalpha, which is recognized by 30 kDa receptor of macrophages. Furthermore, other Leishmania species, such as Leishmania (Leishmania) major and Leishmania (Viannia) braziliensis present glycosylinositolphospholipids (GIPLs) which are involved in Leishmania-macrophage interaction. It is worth to mention that these antigens are not expressed in mammalian cells. Leishmania promastigotes also present inositol phosphorylceramide (IPC), a unique sphingolipid characteristic of fungi and plants. It was observed that IPC synthesis is essential for parasite division, since Aureobasidin A, an inhibitor of IPC synthase, inhibited significantly promastigote and amastigote growths. Recently, it was also demonstrated that GIPLs, IPC and sterols are preferentially present in the parasite membrane microdomains resistant to Triton X-100 at 4 degrees C. The disruption of these microdomains by incubating parasites with methyl-beta-cyclodextrin inhibited significantly macrophage infectivity by Leishmania. Other pathogens, such as fungi, also present unique glycolipids which may have an important role for the fungal development and/or disease establishment. Taking together these results, this review will discuss different biological roles for (glyco)(sphingo)lipids of different pathogens.
Suzuki
Erika
E
Division of Glycoconjugate Immunochemistry, Department of Biochemistry, Ed. J.L. Prado, Rua Botucatu, 862, 04023-900, São Paulo, SP, Brazil.
Tanaka
Ameria K
AK
Toledo
Marcos S
MS
Levery
Steven B
SB
Straus
Anita H
AH
Takahashi
Helio K
HK
D000818:Animals; D003141:Communicable Diseases / Q000378:metabolism / Q000628:therapy*; D005658:Fungi / Q000472:pathogenicity*; D006017:Glycolipids / Q000378:metabolism*; D013107:Sphingolipids / Q000378:metabolism*; D014345:Trypanosoma / Q000472:pathogenicity*; D037521:Virulence Factors / Q000378:metabolism*
D006017:Glycolipids; D013107:Sphingolipids; D037521:Virulence Factors